2024-09-24 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis: 

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that researches, develops, and commercializes medicines for a wide range of diseases.

**Performance Analysis:**

**1. Performance Compared to S&P 500:**

* **Cumulative Return (GILD):** -12.88%
* **Cumulative Return (VOO):** 132.53%
* **Performance Gap:** -145.41% (Relative Gap: 6.43%)

Gilead Sciences has significantly underperformed the S&P 500 over the period analyzed. The relative gap of 6.43% indicates that the current performance gap is in the lower 6.43% percentile of historical performance gaps. 

**2. Recent Price Movements:**

* **Closing Price:** $83.94
* **5-day Moving Average:** $83.69
* **20-day Moving Average:** $80.50
* **60-day Moving Average:** $75.35

The stock price is currently trading above all three moving averages, indicating a positive short-term trend.

**3. Technical Indicators:**

* **RSI:** 76.22
* **PPO:** 0.25
* **Delta_Previous_Relative_Divergence:** 1.13 (Positive)
* **Expected Return:** 18.37%

The RSI is above 70, indicating an overbought condition. The PPO is positive, suggesting a potential bullish trend. The positive Delta_Previous_Relative_Divergence signals a short-term upward trend. The expected return of 18.37% represents the potential 5-year return on investment, assuming current market conditions hold.

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue     |
|-----------|---------|-------------|
| 2024-08-08 | 1.29    | $6.95 Billion |
| 2024-05-08 | -3.34   | $6.69 Billion |
| 2023-11-07 | 1.75    | $7.05 Billion |
| 2023-08-04 | 0.84    | $6.60 Billion |
| 2024-08-08 | 0.84    | $6.60 Billion |

The most recent earnings report for Q2 2024 showed EPS of $1.29, exceeding analysts' expectations of $0.98. Revenue also beat expectations, coming in at $6.95 billion compared to the expected $6.80 billion. 

**Overall Analysis:**

Gilead Sciences has lagged behind the S&P 500 in terms of long-term performance. However, recent price action and the latest earnings report suggest a potential short-term uptrend. Technical indicators are mixed, with RSI suggesting an overbought condition, while PPO and Delta_Previous_Relative_Divergence point towards potential bullish momentum. The company's strong earnings performance indicates a positive outlook, and the expected return of 18.37% presents a potential attractive investment opportunity. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered as investment advice. It is recommended to consult with a financial professional before making any investment decisions. 
